Search Results - "Solit, David"

Clinical cancer genomic profiling by Chakravarty, Debyani, Solit, David B.

“…Technological innovation and rapid reduction in sequencing costs have enabled the genomic profiling of hundreds of cancer-associated genes as a component of…”
Get full text

Tumor adaptation and resistance to RAF inhibitors by Lito, Piro, Rosen, Neal, Solit, David B

“…Inhibitors of RAF kinase have shown substantial benefits in the clinic for the treatment of people with BRAF-mutant melanoma, but their utility is limited by…”
Get full text

Resistance to BRAF Inhibition in Melanomas by Solit, David B, Rosen, Neal

“…PLX4032, an inhibitor of activated BRAF, has shown clinical efficacy in treating patients with melanomas carrying an activating mutation in BRAF, but…”
Get full text

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition by Yao, Zhan, Torres, Neilawattie M., Tao, Anthony, Gao, Yijun, Luo, Lusong, Li, Qi, de Stanchina, Elisa, Abdel-Wahab, Omar, Solit, David B., Poulikakos, Poulikos I., Rosen, Neal

“…ERK signaling requires RAS-induced RAF dimerization and is limited by feedback. Activated BRAF mutants evade feedback inhibition of RAS by either of two…”
Get full text

Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting by Yaeger, Rona, Solit, David B

“…KRAS G12C inhibitors have shown promise in KRAS G12C-mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the…”
Get full text

BRAF — a tumour-agnostic drug target with lineage-specific dependencies by Hanrahan, Aphrothiti J., Chen, Ziyu, Rosen, Neal, Solit, David B.

“…In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib for the treatment of adult…”
Get full text

Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions by Brannon, A Rose, Vakiani, Efsevia, Sylvester, Brooke E, Scott, Sasinya N, McDermott, Gregory, Shah, Ronak H, Kania, Krishan, Viale, Agnes, Oschwald, Dayna M, Vacic, Vladimir, Emde, Anne-Katrin, Cercek, Andrea, Yaeger, Rona, Kemeny, Nancy E, Saltz, Leonard B, Shia, Jinru, D'Angelica, Michael I, Weiser, Martin R, Solit, David B, Berger, Michael F

“…Colorectal cancer is the second leading cause of cancer death in the United States, with over 50,000 deaths estimated in 2014. Molecular profiling for somatic…”
Get full text

Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer by Lee, Suk Hyung, Hu, Wenhuo, Matulay, Justin T., Silva, Mark V., Owczarek, Tomasz B., Kim, Kwanghee, Chua, Chee Wai, Barlow, LaMont J., Kandoth, Cyriac, Williams, Alanna B., Bergren, Sarah K., Pietzak, Eugene J., Anderson, Christopher B., Benson, Mitchell C., Coleman, Jonathan A., Taylor, Barry S., Abate-Shen, Cory, McKiernan, James M., Al-Ahmadie, Hikmat, Solit, David B., Shen, Michael M.

“…Bladder cancer is the fifth most prevalent cancer in the U.S., yet is understudied, and few laboratory models exist that reflect the biology of the human…”
Get full text

Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies by Harding, James J, Nandakumar, Subhiksha, Armenia, Joshua, Khalil, Danny N, Albano, Melanie, Ly, Michele, Shia, Jinru, Hechtman, Jaclyn F, Kundra, Ritika, El Dika, Imane, Do, Richard K, Sun, Yichao, Kingham, T Peter, D'Angelica, Michael I, Berger, Michael F, Hyman, David M, Jarnagin, William, Klimstra, David S, Janjigian, Yelena Y, Solit, David B, Schultz, Nikolaus, Abou-Alfa, Ghassan K

“…Prior molecular profiling of hepatocellular carcinoma (HCC) has identified actionable findings that may have a role in guiding therapeutic decision-making and…”
Get full text

Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity by Chang, Matthew T, Asthana, Saurabh, Gao, Sizhi Paul, Lee, Byron H, Chapman, Jocelyn S, Kandoth, Cyriac, Gao, JianJiong, Socci, Nicholas D, Solit, David B, Olshen, Adam B, Schultz, Nikolaus, Taylor, Barry S

“…Detection of recurrently mutated nucleotides identifies novel cancer hotspots in an analysis of >11,000 human tumor samples. Mutational hotspots indicate…”
Get full text

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers by Teo, Min Yuen, Seier, Kenneth, Ostrovnaya, Irina, Regazzi, Ashley M, Kania, Brooke E, Moran, Meredith M, Cipolla, Catharine K, Bluth, Mark J, Chaim, Joshua, Al-Ahmadie, Hikmat, Snyder, Alexandra, Carlo, Maria I, Solit, David B, Berger, Michael F, Funt, Samuel, Wolchok, Jedd D, Iyer, Gopa, Bajorin, Dean F, Callahan, Margaret K, Rosenberg, Jonathan E

“…Purpose Alterations in DNA damage response and repair (DDR) genes are associated with increased mutation load and improved clinical outcomes in…”
Get full text

Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention by Lowery, Maeve A, Ptashkin, Ryan, Jordan, Emmet, Berger, Michael F, Zehir, Ahmet, Capanu, Marinela, Kemeny, Nancy E, O'Reilly, Eileen M, El-Dika, Imane, Jarnagin, William R, Harding, James J, D'Angelica, Michael I, Cercek, Andrea, Hechtman, Jaclyn F, Solit, David B, Schultz, Nikolaus, Hyman, David M, Klimstra, David S, Saltz, Leonard B, Abou-Alfa, Ghassan K

“…Various genetic driver aberrations have been identified among distinct anatomic and clinical subtypes of intrahepatic and extrahepatic cholangiocarcinoma, and…”
Get full text

Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy by Wang, Yujue, Liu, Sixue, Yang, Zhentao, Algazi, Alain P., Lomeli, Shirley H., Wang, Yan, Othus, Megan, Hong, Aayoung, Wang, Xiaoyan, Randolph, Chris E., Jones, Alexis M., Bosenberg, Marcus W., Byrum, Stephanie D., Tackett, Alan J., Lopez, Henry, Yates, Clayton, Solit, David B., Ribas, Antoni, Piva, Marco, Moriceau, Gatien, Lo, Roger S.

“…Rationally sequencing and combining PD-1/L1-and MAPK-targeted therapies may overcome innate and acquired resistance. Since increased clinical benefit of MAPK…”
Get full text

KRAS and BRAF: drug targets and predictive biomarkers by Vakiani, Efsevia, Solit, David B

“…Three decades have passed since RAS was first identified as the transformative factor in the Harvey and Kirsten strains of the mouse sarcoma virus. RAS and…”
Get full text

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets by Pietzak, Eugene J, Bagrodia, Aditya, Cha, Eugene K, Drill, Esther N, Iyer, Gopa, Isharwal, Sumit, Ostrovnaya, Irina, Baez, Priscilla, Li, Qiang, Berger, Michael F, Zehir, Ahmet, Schultz, Nikolaus, Rosenberg, Jonathan E, Bajorin, Dean F, Dalbagni, Guido, Al-Ahmadie, Hikmat, Solit, David B, Bochner, Bernard H

“…Abstract Background Molecular characterization of nonmuscle invasive bladder cancer (NMIBC) may provide a biologic rationale for treatment response and novel…”
Get full text

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer by Yaeger, Rona, Chatila, Walid K., Lipsyc, Marla D., Hechtman, Jaclyn F., Cercek, Andrea, Sanchez-Vega, Francisco, Jayakumaran, Gowtham, Middha, Sumit, Zehir, Ahmet, Donoghue, Mark T.A., You, Daoqi, Viale, Agnes, Kemeny, Nancy, Segal, Neil H., Stadler, Zsofia K., Varghese, Anna M., Kundra, Ritika, Gao, Jianjiong, Syed, Aijazuddin, Hyman, David M., Vakiani, Efsevia, Rosen, Neal, Taylor, Barry S., Ladanyi, Marc, Berger, Michael F., Solit, David B., Shia, Jinru, Saltz, Leonard, Schultz, Nikolaus

“…Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis of this variability remains poorly understood. We performed…”
Get full text

Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non-Small Cell Lung Cancer by Arbour, Kathryn C, Jordan, Emmett, Kim, Hyunjae Ryan, Dienstag, Jordan, Yu, Helena A, Sanchez-Vega, Francisco, Lito, Piro, Berger, Michael, Solit, David B, Hellmann, Matthew, Kris, Mark G, Rudin, Charles M, Ni, Ai, Arcila, Maria, Ladanyi, Marc, Riely, Gregory J

“…mutations occur in approximately 25% of patients with non-small cell lung cancer (NSCLC). Despite the uniform presence of mutations, patients with -mutant…”
Get full text

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial by Janjigian, Yelena Y, Maron, Steven B, Chatila, Walid K, Millang, Brittanie, Chavan, Shweta S, Alterman, Carly, Chou, Joanne F, Segal, Michal F, Simmons, Marc Z, Momtaz, Parisa, Shcherba, Marina, Ku, Geoffrey Y, Zervoudakis, Alice, Won, Elizabeth S, Kelsen, David P, Ilson, David H, Nagy, Rebecca J, Lanman, Richard B, Ptashkin, Ryan N, Donoghue, Mark T A, Capanu, Marinela, Taylor, Barry S, Solit, David B, Schultz, Nikolaus, Hechtman, Jaclyn F

“…Addition of trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety…”
Get full text

Lessons from the Study of Exceptional Responders by Elzein, Arijh, Iyer, Gopa, Solit, David B

“…In this issue of Cancer Cell, Wheeler et al. report that mechanisms of exceptional response to cancer treatment can be grouped into four broad categories:…”
Get full text

Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes by Coombs, Catherine C., Zehir, Ahmet, Devlin, Sean M., Kishtagari, Ashwin, Syed, Aijazuddin, Jonsson, Philip, Hyman, David M., Solit, David B., Robson, Mark E., Baselga, José, Arcila, Maria E., Ladanyi, Marc, Tallman, Martin S., Levine, Ross L., Berger, Michael F.

“…Clonal hematopoiesis (CH), as evidenced by recurrent somatic mutations in leukemia-associated genes, commonly occurs among aging human hematopoietic stem…”
Get full text